We have developed an integrated drug development platform with established manufacturing and commercialization capabilities that have been in operation for 20 years. Those capabilities distinguish ourselves in the novel drug market, and are highly synergistic with our R&D processes, to provide a strong competitive position in the industry.
Our two manufacturing facilities in Shenyang hold GMP manufacturing certificates operated for 20 years, with facilities of 700 million units of tablets, 300 million units of hard capsules and 1.0 million bottles of drug mixtures to support our current and future manufacturing needs. Our facilities and production lines are fully automated, with continuous performance verification to ensure long-term and stable operations. All the drugs used for the R&D activities of our MT-1207, PE-001 and PH-501 are manufactured in our existing manufacturing facilities.
